StreetInsider.com News Articles

After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

Wed, 27 May 2026 09:00:00 -0400

Issued on behalf of Conexeu Sciences Inc.

Conexeu Sciences just 3D-bioprinted a new tissue matrix to one of the most respected regenerative medicine institutes in the world. For investors watching how breast reconstruction — and the wider field of tissue regeneration — evolves, the next 18 months matter.

NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary — For more than fifty years, breast reconstruction has mostly meant one thing: replacement. A silicone shell, filled with gel, designed to restore shape and volume, none of them designed to regenerate the

After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

Wed, 27 May 2026 09:00:00 -0400

Issued on behalf of Conexeu Sciences Inc.

After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

Wed, 27 May 2026 09:00:00 -0400

Issued on behalf of Conexeu Sciences Inc.

After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

Wed, 27 May 2026 09:00:00 -0400

Issued on behalf of Conexeu Sciences Inc.

After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

Wed, 27 May 2026 09:00:00 -0400

Issued on behalf of Conexeu Sciences Inc.

After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

Wed, 27 May 2026 09:00:00 -0400

Issued on behalf of Conexeu Sciences Inc.

After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

Wed, 27 May 2026 09:00:00 -0400

Issued on behalf of Conexeu Sciences Inc.

After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

Wed, 27 May 2026 09:00:00 -0400

Issued on behalf of Conexeu Sciences Inc.

After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

Wed, 27 May 2026 09:00:00 -0400

Issued on behalf of Conexeu Sciences Inc.

After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

Wed, 27 May 2026 09:00:00 -0400

Issued on behalf of Conexeu Sciences Inc.

After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

Wed, 27 May 2026 09:00:00 -0400

Issued on behalf of Conexeu Sciences Inc.

After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

Wed, 27 May 2026 09:00:00 -0400

Issued on behalf of Conexeu Sciences Inc.

Form 3 InMode Ltd. For: May 19 Filed by: Nass Shlomo

Tue, 26 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260526/26550584.html

Form 3 InMode Ltd. For: May 19 Filed by: Nass Shlomo

Tue, 26 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260526/26550584.html

Form 3 InMode Ltd. For: May 19 Filed by: Moshe Itzkovich

Tue, 26 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260526/26550585.html

Form 3 InMode Ltd. For: May 19 Filed by: Moshe Itzkovich

Tue, 26 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260526/26550585.html

Form 6-K InMode Ltd. For: May 20

Wed, 20 May 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260520/26524719.html

Form 6-K InMode Ltd. For: May 20

Wed, 20 May 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260520/26524719.html

InMode names new chairman and CFO in leadership changes

Wed, 20 May 2026 07:00:25 -0400

InMode Ltd. (NASDAQ: INMD) announced the appointment of Dr. Shlomo Nass as Chairman of the Board of Directors and Moshik Itzkovich as Chief Financial Officer, effective immediately.

Dr. Nass succeeds Dr. Michael Anghel, who retired earlier this month. The company stated that Dr. Nass brings experience in corporate law, accounting, governance, and audit oversight, with background advising public and private companies on regulatory and financial matters.

"His deep expertise in corporate governance, financial oversight, and regulatory matters, combined with his extensive leadership experience, will be invaluable as we continue to execute our strategic priorities and drive long-term shareholder value," said Moshe Mizrahy,

InMode names new chairman and CFO in leadership changes

Wed, 20 May 2026 07:00:25 -0400

InMode Ltd. (NASDAQ: INMD) announced the appointment of Dr. Shlomo Nass as Chairman of the Board of Directors and Moshik Itzkovich as Chief Financial Officer, effective immediately.

InMode names new chairman and CFO in leadership changes

Wed, 20 May 2026 07:00:25 -0400

InMode Ltd. (NASDAQ: INMD) announced the appointment of Dr. Shlomo Nass as Chairman of the Board of Directors and Moshik Itzkovich as Chief Financial Officer, effective immediately.

InMode names new chairman and CFO in leadership changes

Wed, 20 May 2026 07:00:25 -0400

InMode Ltd. (NASDAQ: INMD) announced the appointment of Dr. Shlomo Nass as Chairman of the Board of Directors and Moshik Itzkovich as Chief Financial Officer, effective immediately.

InMode Appoints Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial Officer

Wed, 20 May 2026 07:00:00 -0400

YOKNEAM, Israel, May 20, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode" or the "Company"), a leading global provider of innovative medical technologies, today announced the appointment of Dr. Shlomo Nass as Chairman of the Company's Board of Directors (the "Board") and Moshik Itzkovich as Chief Financial Officer, effective immediately.

InMode Appoints Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial Officer

Wed, 20 May 2026 07:00:00 -0400

InMode Appoints Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial Officer

Wed, 20 May 2026 07:00:00 -0400